Sosei Assigns AD 923 Assets to Pharmasol
The AD 923 development programme had previously entered Phase III clinical trials in
Based on the present agreement Sosei R&D will receive payments from Pharmasol based on revenues arising from the commercialization of these assigned assets.
Editor's notes: About Sosei
Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into,
For further information about Sosei, please visit http://www.sosei.com
About Pharmasol
Pharmasol Corporation engages in the contract manufacturing, packaging, and warehousing of aerosols, liquids, gels, and lotions for the health care and cosmetics industries. It also offers consultancy services, including research and development, purchasing, and marketing.
For further information about Pharmasol, please visit http://www.pharmasol.co.uk
For further information: Sosei Group Corporation: Kojimachi Tsuruya Hachiman Bldg. 5F, 2-4 Kojimachi, Chiyoda-ku, Tokyo 102-0083 Japan, Hidetoshi Torami, E-mail: [email protected], Tel: +81-3-5210-3399, Fax: +81-3-5210-3291; Sosei R&D Ltd: 1F London BioScience Innovation Centre, 2 Royal College Street, London, NW1 0NH, Dr Michael Murray, Managing Director, E-mail: [email protected], Tel: +44-20-7691-2081, Fax: +44-20-7209-2484
Share this article